Skip to content

Survival Analysis and Long-term Prognosis Factors Analysis of Patients with Coronary Artery Disease After PCI

Survival Analysis and Long-term Prognosis Factors Analysis of Patients with Coronary Artery Disease After PCI

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCS-11001510
Enrollment
Unknown
Registered
2011-08-30
Start date
2005-01-06
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease After PCI

Interventions

1:Nil

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Coronary angiography time is comfirmed and clear; 2. Successful interventional treatment: (1) the residual vascular narrow < 20%; (2) the TIMI flow level is class 3; (3) without intraoperative complications (death, myocardial infarction, emergency coronary bypass); 3. Male and female aged<=80 years-old; 4. the follow-up data is integrity;5. intervention treatment time between January 2005 to August 2009 in the between.

Exclusion criteria

Exclusion criteria: 1. Active tuberculosis or rheumatoid immune disease patients; 2. with severe valve disease or cardiomyopathy; 3. with severe copd, lung or respiratory failure patients; 4. renal dysfunction, male in serum creatinine > 2.5 mg/dl (221 umol/l), women in serum creatinine > 2.0 mg/dl (177 umol/l); 5. serious hematopoietic system disease; 6. serious mental patients; 7. malignant tumor patients; Organ transplant patients.

Design outcomes

Primary

MeasureTime frame
Myocardial Infarction;revascularization;death;

Secondary

MeasureTime frame
other thromboembolic disease;stroke;readmission for angin;

Countries

China

Contacts

Public ContactKeji Chen
chen.keji@gmail.com+86 010 62835039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026